Why the study?
To examine whether scar imaging echocardiography with ultrasound multi-pulse scheme (eSCAR) can detect subclinical myocardial involvement in systemic lupus erythematosus.
Does scar imaging echocardiography with ultrasound multi-pulse scheme (eSCAR) detect subclinical myocardial involvement in asymptomatic patients with systemic lupus erythematosus?
Does scar imaging echocardiography with ultrasound multi-pulse scheme (eSCAR) detect subclinical myocardial involvement in asymptomatic patients with systemic lupus erythematosus?
eSCAR can detect subclinical myocardial fibrosis in approximately one-fifth of asymptomatic SLE patients, which correlates with higher glucocorticoid use and predicts future SLE flares.
eSCAR may detect subclinical myocardial involvement in asymptomatic SLE; hypothesis-generating and requires prospective validation before clinical adoption.
The aim of this study was to examine whether scar imaging echocardiography with ultrasound multi-pulse scheme (eSCAR) can detect subclinical myocardial involvement in systemic lupus erythematosus (SLE). We consecutively recruited SLE patients and controls matched for age, sex, and cardiovascular risk factors. Participants with cardiac symptoms or a prior history of heart disease were excluded. All participants underwent eSCAR and speckle tracking echocardiography (STE) with global longitudinal strain (GLS) assessment. SLE patients were assessed for disease activity and were followed up for 12 months. Myocardial scars by eSCAR were observed in 19% of SLE patients, almost exclusively localized at the inferoseptal myocardial segments, and in none of the controls. GLS was significantly lower in most myocardial segments of SLE patients compared with the controls, especially in the inferoseptal segments. eSCAR-positive SLE patients received a higher cumulative and current dose of prednisone, and had significantly higher levels of anti-dsDNA antibodies (p = 0.037). eSCAR-positive patients were at higher risk of having SLE flares over follow-up (hazard ratio: 4.91; 95% CI 1.43–16.83; p = 0.0001). We identified inferoseptal myocardial scars by eSCAR in about one-fifth of SLE patients. Subclinical myocardial involvement was associated with glucocorticoid use and anti-dsDNA antibodies.
No takes yet. Share an insight, caveat, or question.
Giollo et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: